As a result, based on the existing evidence, it seems that PDK1's impact on drug resistance in NSCLC is part of a multifaceted network of factors, requiring in‐depth laboratory analysis for a complete understanding. The gene discussed is PDK1; the disease is non-small cell lung carcinoma.